{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:10:11Z","timestamp":1793052611265,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008783","name":"National Research Council of Science & Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Seoul Business Agency"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2019R1A2C3006283"],"award-info":[{"award-number":["NRF-2019R1A2C3006283"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Nanomedicine has emerged as a promising strategy for cancer treatment. The most representative nanomedicine used in clinic is PEGylated liposomal doxorubicin DOXIL\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , which is first FDA-approved nanomedicine. However, several shortcomings, such as low drug loading capacity, low tumor targeting, difficulty in mass production and potential toxicity of carrier materials, have hindered the successful clinical translation of nanomedicines. In this study, we report a preclinical development process of the carrier-free prodrug nanoparticles designed as an alternative formulation to overcome limitations of conventional nanomedicines in the terms of technical- and industrial-aspects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The carrier-free prodrug nanoparticles (F68-FDOX) are prepared by self-assembly of cathepsin B-specific cleavable peptide (FRRG) and doxorubicin (DOX) conjugates without any additional carrier materials, and further stabilized with Pluronic F68, resulting in high drug loading (&gt;\u200950%). The precise and concise structure allow mass production with easily controllable quality control (QC), and its lyophilized powder form has a great long-term storage stability at different temperatures (\u2212\u00a04, 37 and 60\u00a0\u00b0C). With high cathepsin B-specificity, F68-FDOX induce a potent cytotoxicity preferentially in cancer cells, whereas their cytotoxicity is greatly minimized in normal cells with innately low cathepsin B expression. In tumor models, F68-FDOX efficiently accumulates within tumor tissues owing to enhanced permeability and retention (EPR) effect and subsequently release toxic DOX molecules by cathepsin B-specific cleavage mechanism, showing a broad therapeutic spectrum with significant antitumor activity in three types of colon, breast and pancreatic cancers. Finally, the safety of F68-FDOX treatment is investigated after single-\/multi-dosage into mice, showing greatly minimized DOX-related toxicity, compared to free DOX in normal mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, these results provide potential preclinical development process of an alternative approach, new formulation of carrier-free prodrug nanoparticles, for clinical translation of nanomedicines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-022-01644-x","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T02:02:39Z","timestamp":1664848959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity"],"prefix":"10.1186","volume":"20","author":[{"given":"Man Kyu","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sik","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujeong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihee","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwhan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmeyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01690-6","author":"A de Gregorio","year":"2022","unstructured":"de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, Kates R, Fehm T, Kreipe H, Christgen M, et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer\u2014a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer. 2022. https:\/\/doi.org\/10.1038\/s41416-021-01690-6.","journal-title":"Br J Cancer"},{"key":"1644_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278: 119527.","journal-title":"Life Sci"},{"key":"1644_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.2009.27.6543","volume":"29","author":"GK Ellis","year":"2011","unstructured":"Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011;29:1014\u201321.","journal-title":"J Clin Oncol"},{"key":"1644_CR4","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-09-2443","volume":"16","author":"S Wang","year":"2010","unstructured":"Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res. 2010;16:2591\u2013604.","journal-title":"Clin Cancer Res"},{"key":"1644_CR5","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood-2016-03-705814","volume":"128","author":"Y Mai","year":"2016","unstructured":"Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, Chen H, Ding BB, Yao Z, Das B, et al. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. Blood. 2016;128:2797\u2013807.","journal-title":"Blood"},{"key":"1644_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/15569543.2021.1912099","volume":"41","author":"K Renu","year":"2022","unstructured":"Renu K, Pureti LP, Vellingiri B, Valsala Gopalakrishnan A. Toxic effects and molecular mechanism of doxorubicin on different organs\u2014an update. Toxin Rev. 2022;41:650\u201374.","journal-title":"Toxin Rev"},{"key":"1644_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22:292\u2013310.","journal-title":"Cardiovasc Toxicol"},{"key":"1644_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12:339.","journal-title":"Cell Death Dis"},{"key":"1644_CR9","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1016\/j.biomaterials.2010.06.054","volume":"31","author":"M Dadsetan","year":"2010","unstructured":"Dadsetan M, Liu Z, Pumberger M, Giraldo CV, Ruesink T, Lu L, Yaszemski MJ. A stimuli-responsive hydrogel for doxorubicin delivery. Biomaterials. 2010;31:8051\u201362.","journal-title":"Biomaterials"},{"key":"1644_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4172\/2157-7439.1000519","volume":"9","author":"N Zhao","year":"2018","unstructured":"Zhao N, Woodle MC, Mixson AJ. Advances in delivery systems for doxorubicin. J Nanomed Nanotechnol. 2018;9:519.","journal-title":"J Nanomed Nanotechnol"},{"key":"1644_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/mt.2016.159","volume":"24","author":"M Zhang","year":"2016","unstructured":"Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E, Xu C, Merlin D. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther. 2016;24:1783\u201396.","journal-title":"Mol Ther"},{"key":"1644_CR12","first-page":"1567","volume":"4","author":"DM Vail","year":"1998","unstructured":"Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4:1567\u201371.","journal-title":"Clin Cancer Res"},{"key":"1644_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"1644_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","volume":"63","author":"V Torchilin","year":"2011","unstructured":"Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131\u20135.","journal-title":"Adv Drug Deliv Rev"},{"key":"1644_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41551-018-0314-y","volume":"2","author":"JPA Ioannidis","year":"2018","unstructured":"Ioannidis JPA, Kim BYS, Trounson A. How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nat Biomed Eng. 2018;2:797\u2013809.","journal-title":"Nat Biomed Eng"},{"key":"1644_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114177","volume":"183","author":"M Kyu Shim","year":"2022","unstructured":"Kyu Shim M, Yang S, Sun I-C, Kim K. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: preclinical evidence for safe and effective drug delivery. Adv Drug Deliv Rev. 2022;183: 114177.","journal-title":"Adv Drug Deliv Rev"},{"key":"1644_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","volume":"20","author":"K Shiraishi","year":"2019","unstructured":"Shiraishi K, Yokoyama M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. Sci Technol Adv Mater. 2019;20:324\u201336.","journal-title":"Sci Technol Adv Mater"},{"key":"1644_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"JI Hare","year":"2017","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25\u201338.","journal-title":"Adv Drug Deliv Rev"},{"key":"1644_CR19","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1007\/s12274-022-4354-y","volume":"15","author":"SI Jeon","year":"2022","unstructured":"Jeon SI, Yang S, Shim MK, Kim K. Cathepsin B-responsive prodrugs for cancer-targeted therapy: recent advances and progress for clinical translation. Nano Res. 2022;15:7247\u201366.","journal-title":"Nano Res"},{"key":"1644_CR20","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.","journal-title":"Nat Rev Mater"},{"key":"1644_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jconrel.2020.10.065","volume":"330","author":"J Kim","year":"2021","unstructured":"Kim J, Shim MK, Yang S, Moon Y, Song S, Choi J, Kim J, Kim K. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. J Control Release. 2021;330:920\u201332.","journal-title":"J Control Release"},{"key":"1644_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jconrel.2018.11.032","volume":"294","author":"MK Shim","year":"2019","unstructured":"Shim MK, Park J, Yoon HY, Lee S, Um W, Kim J-H, Kang S-W, Seo J-W, Hyun S-W, Park JH, et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J Control Release. 2019;294:376\u201389.","journal-title":"J Control Release"},{"key":"1644_CR23","doi-asserted-by":"publisher","first-page":"2101460","DOI":"10.1002\/smll.202101460","volume":"17","author":"G Li","year":"2021","unstructured":"Li G, Sun B, Li Y, Luo C, He Z, Sun J. Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery. Small. 2021;17:2101460.","journal-title":"Small"},{"key":"1644_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jconrel.2018.12.014","volume":"294","author":"W-R Zhuang","year":"2019","unstructured":"Zhuang W-R, Wang Y, Cui P-F, Xing L, Lee J, Kim D, Jiang H-L, Oh Y-K. Applications of \u03c0\u2013\u03c0 stacking interactions in the design of drug-delivery systems. J Control Release. 2019;294:311\u201326.","journal-title":"J Control Release"},{"key":"1644_CR25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.7150\/thno.69119","volume":"12","author":"Y Moon","year":"2022","unstructured":"Moon Y, Shim MK, Choi J, Yang S, Kim J, Yun WS, Cho H, Park JY, Kim Y, Seong J-K, Kim K. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022;12:1999\u20132014.","journal-title":"Theranostics"},{"key":"1644_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.actbio.2020.07.007","volume":"113","author":"L Zhou","year":"2020","unstructured":"Zhou L, Xie H, Chen X, Wan J, Xu S, Han Y, Chen D, Qiao Y, Zhou L, Zheng S, Wang H. Dimerization-induced self-assembly of a redox-responsive prodrug into nanoparticles for improved therapeutic index. Acta Biomater. 2020;113:464\u201377.","journal-title":"Acta Biomater"},{"key":"1644_CR27","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1158\/0008-5472.CAN-17-0984","volume":"77","author":"H Wang","year":"2017","unstructured":"Wang H, Lu Z, Wang L, Guo T, Wu J, Wan J, Zhou L, Li H, Li Z, Jiang D, et al. New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Can Res. 2017;77:6963\u201374.","journal-title":"Can Res"},{"key":"1644_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.101030","volume":"36","author":"L Huang","year":"2021","unstructured":"Huang L, Wan J, Wu H, Chen X, Bian Q, Shi L, Jiang X, Yuan A, Gao J, Wang H. Quantitative self-assembly of photoactivatable small molecular prodrug cocktails for safe and potent cancer chemo-photodynamic therapy. Nano Today. 2021;36: 101030.","journal-title":"Nano Today"},{"key":"1644_CR29","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.7150\/thno.55250","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Xie B, Huang L, Wan J, Wang Y, Shi X, Qiao Y, Song H, Wang H. Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy. Theranostics. 2021;11:5713\u201327.","journal-title":"Theranostics"},{"key":"1644_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1039\/D0NH00469C","volume":"6","author":"X Chen","year":"2021","unstructured":"Chen X, Hu Z, Zhou L, Zhang F, Wan J, Wang H. Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy. Nanoscale Horiz. 2021;6:33\u201342.","journal-title":"Nanoscale Horiz"},{"key":"1644_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2020.08.043","volume":"328","author":"H Xie","year":"2020","unstructured":"Xie H, Zhu H, Zhou K, Wan J, Zhang L, Yang Z, Zhou L, Chen X, Xu X, Zheng S, Wang H. Target-oriented delivery of self-assembled immunosuppressant cocktails prolongs allogeneic orthotopic liver transplant survival. J Control Release. 2020;328:237\u201350.","journal-title":"J Control Release"},{"key":"1644_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120791","volume":"272","author":"S Yang","year":"2021","unstructured":"Yang S, Shim MK, Kim WJ, Choi J, Nam G-H, Kim J, Kim J, Moon Y, Kim HY, Park J, et al. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials. 2021;272: 120791.","journal-title":"Biomaterials"},{"key":"1644_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121189","volume":"279","author":"J Kim","year":"2021","unstructured":"Kim J, Shim MK, Cho Y-J, Jeon S, Moon Y, Choi J, Kim J, Lee J, Lee J-W, Kim K. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021;279: 121189.","journal-title":"Biomaterials"},{"key":"1644_CR34","doi-asserted-by":"publisher","first-page":"12086","DOI":"10.1021\/acsnano.1c03416","volume":"15","author":"J Choi","year":"2021","unstructured":"Choi J, Shim MK, Yang S, Hwang HS, Cho H, Kim J, Yun WS, Moon Y, Kim J, Yoon HY, Kim K. Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. ACS Nano. 2021;15:12086\u201398.","journal-title":"ACS Nano"},{"key":"1644_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010083","author":"H Cho","year":"2022","unstructured":"Cho H, Shim MK, Yang S, Song S, Moon Y, Kim J, Byun Y, Ahn C-H, Kim K. Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14010083.","journal-title":"Pharmaceutics"},{"key":"1644_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2021.07.014","volume":"337","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Javia A, Shetty S, Bardoliwala D, Maiti K, Banerjee S, Khopade A, Misra A, Sawant K, Bhowmick S. Triple negative breast cancer and non-small cell lung cancer: clinical challenges and nano-formulation approaches. J Control Release. 2021;337:27\u201358.","journal-title":"J Control Release"},{"key":"1644_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jcis.2006.07.031","volume":"302","author":"MJ Santander-Ortega","year":"2006","unstructured":"Santander-Ortega MJ, J\u00f3dar-Reyes AB, Csaba N, Bastos-Gonz\u00e1lez D, Ortega-Vinuesa JL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J Colloid Interface Sci. 2006;302:522\u20139.","journal-title":"J Colloid Interface Sci"},{"key":"1644_CR38","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/jm00185a004","volume":"23","author":"R Baurain","year":"1980","unstructured":"Baurain R, Masquelier M, Deprez-De Campeneere D, Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity of L1210 leukemic cells in vitro and in vivo. J Med Chem. 1980;23:1171\u20134.","journal-title":"J Med Chem"},{"key":"1644_CR39","doi-asserted-by":"publisher","first-page":"14698","DOI":"10.1002\/anie.201608504","volume":"55","author":"MK Shim","year":"2016","unstructured":"Shim MK, Yoon HY, Ryu JH, Koo H, Lee S, Park JH, Kim J-H, Lee S, Pomper MG, Kwon IC, Kim K. Cathepsin B-specific metabolic precursor for in vivo tumor-specific fluorescence imaging. Angew Chem Int Ed. 2016;55:14698\u2013703.","journal-title":"Angew Chem Int Ed"},{"key":"1644_CR40","first-page":"137","volume":"1","author":"BF Sloane","year":"1990","unstructured":"Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1990;1:137\u201352.","journal-title":"Semin Cancer Biol"},{"key":"1644_CR41","doi-asserted-by":"publisher","first-page":"128ra139","DOI":"10.1126\/scitranslmed.3003651","volume":"4","author":"J Hrkach","year":"2012","unstructured":"Hrkach J, Von Hoff D, Ali Mir M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128ra139.","journal-title":"Sci Transl Med"},{"key":"1644_CR42","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.1002\/anie.200902612","volume":"48","author":"Z Liu","year":"2009","unstructured":"Liu Z, Fan AC, Rakhra K, Sherlock S, Goodwin A, Chen X, Yang Q, Felsher DW, Dai H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed. 2009;48:7668\u201372.","journal-title":"Angew Chem Int Ed"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01644-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01644-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01644-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T14:03:19Z","timestamp":1664892199000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01644-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01644-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mice were bred under pathogen-free conditions in the Korea Institute of Science and Technology (KIST). All experiments with animals were performed in compliance with the relevant laws and institutional guidelines of Institutional Animal Care and Use Committee (IACUC; Approved Number of 2020-123) in Korea Institute of Science and Technology (KIST).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}